122 related articles for article (PubMed ID: 31286212)
1. Molecular Mechanisms of Amphetamines.
Reith MEA; Gnegy ME
Handb Exp Pharmacol; 2020; 258():265-297. PubMed ID: 31286212
[TBL] [Abstract][Full Text] [Related]
2. Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice.
Patel J; Mooslehner KA; Chan PM; Emson PC; Stamford JA
J Neurochem; 2003 May; 85(4):898-910. PubMed ID: 12716422
[TBL] [Abstract][Full Text] [Related]
3. Role of Organic Cation Transporter 3 and Plasma Membrane Monoamine Transporter in the Rewarding Properties and Locomotor Sensitizing Effects of Amphetamine in Male andFemale Mice.
Clauss NJ; Koek W; Daws LC
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948221
[TBL] [Abstract][Full Text] [Related]
4. The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficits.
Volz TJ; Hanson GR; Fleckenstein AE
J Neurochem; 2007 May; 101(4):883-8. PubMed ID: 17250674
[TBL] [Abstract][Full Text] [Related]
5. PKC phosphorylates residues in the N-terminal of the DA transporter to regulate amphetamine-induced DA efflux.
Wang Q; Bubula N; Brown J; Wang Y; Kondev V; Vezina P
Neurosci Lett; 2016 May; 622():78-82. PubMed ID: 27113203
[TBL] [Abstract][Full Text] [Related]
6. New insights into the mechanism of action of amphetamines.
Fleckenstein AE; Volz TJ; Riddle EL; Gibb JW; Hanson GR
Annu Rev Pharmacol Toxicol; 2007; 47():681-98. PubMed ID: 17209801
[TBL] [Abstract][Full Text] [Related]
7. Expression of dopamine transporter and vesicular monoamine transporter 2 mRNAs in rat midbrain after repeated amphetamine administration.
Lu W; Wolf ME
Brain Res Mol Brain Res; 1997 Oct; 49(1-2):137-48. PubMed ID: 9387873
[TBL] [Abstract][Full Text] [Related]
8. An unsuspected role for organic cation transporter 3 in the actions of amphetamine.
Mayer FP; Schmid D; Owens WA; Gould GG; Apuschkin M; Kudlacek O; Salzer I; Boehm S; Chiba P; Williams PH; Wu HH; Gether U; Koek W; Daws LC; Sitte HH
Neuropsychopharmacology; 2018 Nov; 43(12):2408-2417. PubMed ID: 29773909
[TBL] [Abstract][Full Text] [Related]
9. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity.
Takahashi N; Miner LL; Sora I; Ujike H; Revay RS; Kostic V; Jackson-Lewis V; Przedborski S; Uhl GR
Proc Natl Acad Sci U S A; 1997 Sep; 94(18):9938-43. PubMed ID: 9275230
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter.
Pifl C; Drobny H; Reither H; Hornykiewicz O; Singer EA
Mol Pharmacol; 1995 Feb; 47(2):368-73. PubMed ID: 7870046
[TBL] [Abstract][Full Text] [Related]
11. [Monoamine transporter as a target molecule for psychostimulants].
Sora I; Igari M; Yamamoto H; Ikeda K
Nihon Yakurigaku Zasshi; 2007 Dec; 130(6):450-4. PubMed ID: 18079593
[No Abstract] [Full Text] [Related]
12. Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate amphetamine-induced reverse transport.
Fog JU; Khoshbouei H; Holy M; Owens WA; Vaegter CB; Sen N; Nikandrova Y; Bowton E; McMahon DG; Colbran RJ; Daws LC; Sitte HH; Javitch JA; Galli A; Gether U
Neuron; 2006 Aug; 51(4):417-29. PubMed ID: 16908408
[TBL] [Abstract][Full Text] [Related]
13. Rebound hypersomnolence, stimulant abuse, and DAT-mediated dopamine release.
Nishino S
Sleep; 2009 Nov; 32(11):1407-9. PubMed ID: 19928377
[No Abstract] [Full Text] [Related]
14. Methamphetamine-induced locomotor activity and sensitization in dopamine transporter and vesicular monoamine transporter 2 double mutant mice.
Fukushima S; Shen H; Hata H; Ohara A; Ohmi K; Ikeda K; Numachi Y; Kobayashi H; Hall FS; Uhl GR; Sora I
Psychopharmacology (Berl); 2007 Jul; 193(1):55-62. PubMed ID: 17377774
[TBL] [Abstract][Full Text] [Related]
15. Amphetamine activates Rho GTPase signaling to mediate dopamine transporter internalization and acute behavioral effects of amphetamine.
Wheeler DS; Underhill SM; Stolz DB; Murdoch GH; Thiels E; Romero G; Amara SG
Proc Natl Acad Sci U S A; 2015 Dec; 112(51):E7138-47. PubMed ID: 26553986
[TBL] [Abstract][Full Text] [Related]
16. Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones.
Rickli A; Hoener MC; Liechti ME
Eur Neuropsychopharmacol; 2015 Mar; 25(3):365-76. PubMed ID: 25624004
[TBL] [Abstract][Full Text] [Related]
17. Amphetamine-induced decreases in dopamine transporter surface expression are protein kinase C-independent.
Boudanova E; Navaroli DM; Melikian HE
Neuropharmacology; 2008 Mar; 54(3):605-12. PubMed ID: 18164041
[TBL] [Abstract][Full Text] [Related]
18. Role of monoamine transporters in mediating psychostimulant effects.
Riddle EL; Fleckenstein AE; Hanson GR
AAPS J; 2005 Dec; 7(4):E847-51. PubMed ID: 16594636
[TBL] [Abstract][Full Text] [Related]
19. Influence of a low dose of amphetamine on vesicular monoamine transporter binding: a PET (+)[11C]DTBZ study in humans.
Boileau I; Houle S; Rusjan PM; Furukawa Y; Wilkins D; Tong J; Selby P; Wilson AA; Kish SJ
Synapse; 2010 Jun; 64(6):417-20. PubMed ID: 20169578
[TBL] [Abstract][Full Text] [Related]
20. N-terminus regulation of VMAT2 mediates methamphetamine-stimulated efflux.
Torres B; Ruoho AE
Neuroscience; 2014 Feb; 259():194-202. PubMed ID: 24321511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
